抗白介素增強子結合因子3(ILF3)多克隆抗體
Anti-Interleukin Enhancer Binding Factor 3 (ILF3) Polyclonal Antibody
DRBF; DRBP76; MMP4; MPHOSPH4; MPP4; NFAT; NF-AT-90; NF90; NFAR1; TCP80; Nuclear Factor Of Activated T-Cells; M-Phase Phosphoprotein 4
- 編號FAA504Hu01
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 效價-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 激發(fā)波長-
- 單次使用量1-5 μl
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 且適物種-
- 應用FCM
- 下載英文說明書 中文說明書
- 規(guī)格25test50test100test200test500test
- 價格¥ 720¥ 1200¥ 1920¥ 2400¥ 4200
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Human Hela cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20μg/ml rabbit Anti-human ILF3 Polyclonal Antibody (Catalog FAA504Hu01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1μg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
Human K562 cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20μg/ml rabbit Anti-human ILF3 Polyclonal Antibody (Catalog FAA504Hu01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1μg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
通過ISO 9001、ISO 13485質(zhì)量體系認證
用法
For flow cytometry, the suggested use of this reagent is 1-5 μl per 10^6 cells in 100 μl volume.
Optimal working dilutions could be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過一年。避免反復凍融。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA504Hu01 | 白介素增強子結合因子3(ILF3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA504Hu01 | 白介素增強子結合因子3(ILF3)多克隆抗體 | WB; IHC; FCM |
| FAA504Hu01 | 抗白介素增強子結合因子3(ILF3)多克隆抗體 | FCM |
| SEA504Hu | 白介素增強子結合因子3(ILF3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA504Hu | 白介素增強子結合因子3(ILF3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |